DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the SYNCOM FORMU (I) LTD (SYNCOMF) share price today?

SYNCOM FORMU (I) LTD (SYNCOMF) is trading at ₹13.47 on the NSE, down 1.68% on the day. Source: DocStoX.

What is the PE ratio of SYNCOM FORMU (I) LTD?

SYNCOM FORMU (I) LTD has a price-to-earnings (PE) ratio of 25.9 in the Healthcare sector.

What is the market capitalisation of SYNCOM FORMU (I) LTD?

SYNCOM FORMU (I) LTD has a market capitalisation of approximately ₹1,269 crore.

SYNCOM FORMU (I) LTD

SYNCOMF·NSE·Healthcare

₹13.47▼ -0.23 (-1.68%)

Healthcare · Pharmaceuticals

Revenue under pressure recently

Day₹13.30

₹13.70

52W₹10

₹2035%

Open

₹13.67

High

₹13.70

Low

₹13.30

Prev Close

₹13.70

Volume

16.16L

VWAP

₹13.48

Snapshot

Key fundamentals

Market Cap

₹1,269 Cr

P/E Ratio

25.90Fair

P/B Ratio

3.17

EPS

₹0.52

Book Value

₹4.41

ROE

14.45%Average

ROCE

19.00%Efficient

Dividend Yield

0.21%

Debt / Equity

0.00Low

Face Value

₹1.00

52W High

₹19.50

52W Low

₹10.21

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹5

▼ 59.7%downside

Trading at ₹13 — 60% above our estimate

BearFair valueBull

₹5₹5₹7

/100

Business quality — Watch the fundamentals

Growth 0Profitability 48Efficiency 36Valuation 80

Plain English

Our view

Revenue under pressure recently
Virtually debt-free balance sheet
Revenue has been shrinking

Strengths

Virtually debt-free balance sheet
Promoters hold a controlling stake

Risks

Revenue has been shrinking

How we got there

Fair value methods

Residual income

14% ROE fading to 12% over ~10 yrs, on ₹4 book

₹5

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹7

Analyst target

No analyst coverage

—

Blended fair value₹5

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Promoters hold a controlling stake

Bear case

Revenue has been shrinking

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

25.9Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

14.4%Average

Above 15% is considered healthy for Indian equities

ROCE

19.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹1,269 Cr

P/B

3.17

EPS

₹0.52

Div Yield

0.21%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Reasonable

P/E 25.9×

Growth

Strong

+30% rev CAGR

Profitability

Healthy

14.4% ROE

Financial health

Rock solid

D/E 0.00

Momentum

N/A

No technicals

Today

Trading activity

Delivery %53.6%

Turnover₹217.88L Cr

Trades3,703

VWAP₹13.48

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+30.1%

+14.8%

10Y

+10.3%

Profit

+56.4%

+21.4%

10Y

+22.6%

EPS

—

10Y

—

Profile

Pros

Company has reduced debt.
Company is almost debt free.
Company has delivered good profit growth of 21.2% CAGR over last 5 years

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Earnings include an other income of Rs.31.0 Cr.
Working capital days have increased from 103 days to 164 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

51%

Promoter

Promoters

50.6%0.00

Public

45.1%+0.11

FII / FPI

0.2%-0.05

DII

0.0%0.00

Others

4.1%

Total shareholders

4,31,690-10,590 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter50.57%

FII0.21%

Public45.15%

Others4.07%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions